StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) in a note issued to investors on Sunday. The firm set a "hold" rating on the biopharmaceutical company's stock.
VNDA has been the subject of a number of other reports. HC Wainwright assumed coverage on Vanda Pharmaceuticals in a research report on Thursday, October 31st. They issued a "buy" rating and a $18.00 target price for the company. Cantor Fitzgerald increased their price target on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an "overweight" rating in a research note on Thursday, August 1st.
Read Our Latest Stock Report on VNDA
Vanda Pharmaceuticals Trading Down 2.0 %
VNDA opened at $5.00 on Friday. The company's 50-day moving average price is $4.80 and its two-hundred day moving average price is $5.26. Vanda Pharmaceuticals has a twelve month low of $3.32 and a twelve month high of $6.75.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of VNDA. Nantahala Capital Management LLC lifted its position in shares of Vanda Pharmaceuticals by 57.3% during the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company's stock worth $9,003,000 after acquiring an additional 580,265 shares in the last quarter. Profit Investment Management LLC lifted its holdings in Vanda Pharmaceuticals by 159.3% during the 2nd quarter. Profit Investment Management LLC now owns 571,324 shares of the biopharmaceutical company's stock worth $3,228,000 after purchasing an additional 351,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Vanda Pharmaceuticals by 17.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company's stock worth $11,379,000 after purchasing an additional 292,172 shares during the period. Monaco Asset Management SAM purchased a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $1,090,000. Finally, Massachusetts Financial Services Co. MA bought a new stake in shares of Vanda Pharmaceuticals during the third quarter valued at about $864,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.
Vanda Pharmaceuticals Company Profile
(
Get Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Featured Articles
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
